ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer
Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.
Related Articles
Amneal Receives FDA Approval for Lenalidomide Capsules | Blood Cancers Today
Lenalidomide is indicated to treat myeloma in combination with dexamethasone and transfusion-dependent anemia due to myelodysplastic syndromes.
FORTIFI-HN01 Trial Enrolls First Patients for Novel HNSCC Therapy
The FORTIFI-HN01 trial has begun enrolling patients with advanced head and neck cancer to evaluate ficerafusp alfa plus pembrolizumab as a first-line therapy.
CARGO Therapeutics to Discontinue Phase 2 Study of Firi-Cel in R/R LBCL
CARGO Therapeutics announced that it will discontinue the phase 2 FIRCE-1 trial evaluating firi-cel in relapsed/refractory large B-cell lymphoma.
Nab-Paclitaxel Plus SOC Chemo Fails to Improve OS in Newly Diagnosed Advanced Biliary Tract Cancer
Results from SWOG S1815 showed no survival benefit for nab-paclitaxel plus gemcitabine and cisplatin in advanced biliary tract cancer.
Firstborn Twins May Have Higher Risk of Leukemia
New research suggests that firstborn twins may have a greater risk of developing leukemia than second-born twins.
FDA Approves Mirdametinib in Adult/Pediatric NF1-PN
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Olaparib Elicits Improved OS Rates in Platinum-Sensitive, Germline/Somatic BRCA+ Relapsed Ovarian Cancer
A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA…
Hyper-Elevated RNA Polymerase II May Point to Increased Tumor Aggressiveness
Directly measuring gene transcription activity from DNA reveals that hyper-elevated RNA Polymerase II levels are associated with tumor aggressiveness.
Case 1 Presentation—KRAS-Mutated Metastatic NSCLC: First-Line Decision- Making
Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.